Cargando…

The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. Extensive enhancement of glycolysis and reprogramming of lipid metabolism are both associated with the development and progression of PDAC. Previous studies have suggested that various gene signatures could conv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Zhen, Lei, Yubin, Xu, Jin, Shi, Si, Hua, Jie, Zhang, Bo, Meng, Qingcai, Liu, Jiang, Zhang, Yiyin, Wei, Miaoyan, Yu, Xianjun, Liang, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762467/ https://www.ncbi.nlm.nih.gov/pubmed/33226369 http://dx.doi.org/10.18632/aging.104134

Ejemplares similares

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2020)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
por: Meng, Qingcai, et al.
Publicado: (2020)

From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors
por: Wei, Miaoyan, et al.
Publicado: (2021)

Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
por: Tang, Rong, et al.
Publicado: (2023)

Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDAC
por: Dong, Mingwei, et al.
Publicado: (2023)

Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance
por: Zhang, Yiyin, et al.
Publicado: (2019)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma
por: Tan, Zhen, et al.
Publicado: (2021)

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)
por: Li, Jialin, et al.
Publicado: (2023)

Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT
por: Meng, Qingcai, et al.
Publicado: (2023)

The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020)

GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation
por: Meng, Qingcai, et al.
Publicado: (2018)

Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis
por: Fang, Zengli, et al.
Publicado: (2023)

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019)

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner
por: Tan, Zhen, et al.
Publicado: (2022)

Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer
por: Dong, Jia, et al.
Publicado: (2023)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
por: Liu, Xiaomeng, et al.
Publicado: (2019)

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis
por: Rong, Zeyin, et al.
Publicado: (2021)

Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis
por: Fang, Zengli, et al.
Publicado: (2020)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
por: Liu, Xiaomeng, et al.
Publicado: (2022)

Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis
por: Meng, Qingcai, et al.
Publicado: (2017)

Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment
por: Rong, Zeyin, et al.
Publicado: (2021)

Emerging roles of the solute carrier family in pancreatic cancer
por: Wu, Zijian, et al.
Publicado: (2021)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma
por: Huang, Xueyuan, et al.
Publicado: (2023)

Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1)
por: Wei, Miaoyan, et al.
Publicado: (2019)

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer: The function of lipid metabolism reprogramming in pancreatic cancer
por: Guo, Duancheng, et al.
Publicado: (2023)

Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis
por: Yao, Jun, et al.
Publicado: (2021)

An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma
por: Qi, Bing, et al.
Publicado: (2021)

Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer
por: Liang, Chen, et al.
Publicado: (2023)

A Novel Validated Recurrence Stratification System Based on (18)F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer
por: Wei, Miaoyan, et al.
Publicado: (2021)

Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features
por: Lei, Yalan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8or1ia7aeema0ht9nkq0q5sipi